查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985927

美國潛伏性結核感染檢測市場：市場規模、佔有率和趨勢分析（按檢測方法、應用、最終用途和地區分類），細分市場預測（2026-2033 年）

U.S. Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report By Test, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國潛伏性結核感染檢測市場概述

據估計，2025 年美國潛伏性結核病檢測市場規模為 4.2761 億美元，預計到 2033 年將達到 6.5111 億美元，2026 年至 2033 年的複合年成長率為 5.17%。

結核病發病率上升的原因是潛伏性結核感染 (LTBI) 發展為活動性結核病感染的風險增加、擴大結核病診斷的資助計劃以及診斷方法的技術進步。

根據美國疾病管制與預防中心 (CDC) 估計，美國有多達 1,300 萬人感染了潛伏性結核病 (LTBI)，如果不進行治療，大約 5% 到 10% 的感染者會在一生中的某個時候發展為活動性結核病。

此外，對結核病根除和預防醫學日益重視，為潛伏性結核感染（LTBI）檢測市場創造了強勁的成長機會。公共衛生部門日益認知到，美國大多數活動性結核病病例並非由近期感染引起，而是由潛伏性行為感染重新運作所致。因此，國家結核病根除策略正轉向在潛伏性結核感染發展為活動性結核病之前對其進行識別和治療，更加重視早期準確的診斷檢測。

結核病的風險受多種因素影響，包括年齡、潛在疾病和暴露環境，老年人和某些特定環境的人口風險更高。因此，透過檢測和治療對潛伏性結核感染（LTBI）進行管理，對於降低發展為活動性結核病的風險和預防疾病傳播至關重要。增加潛伏性結核感染發展為活動性結核病風險的因素包括：

目錄

第1章：分析方法和範圍

第2章執行摘要

第3章：美國潛伏性結核感染檢測市場：影響因素、趨勢與範圍

  • 市場歷史及展望
    • 母市場展望（潛伏性結核感染檢測市場）
    • 相關/附隨市場展望（結核病診斷市場）
  • 市場動態
  • 美國潛伏性結核感染檢測市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析
  • 法律規範
  • 救贖方案
  • 移民測試的支付和報銷
  • 美國CLIA認證的檢測實驗室
    • 美國所有獲得CLIA認證的檢測實驗室名單
    • 提供經 CLIA 和 NYS 認證的檢查室名單，這些實驗室可進行 QFT (CPT 86480)、T-SPOT.TB (86481) 和 TST (86580) 檢測，並列出檢測次數。
    • 按 NPI、地區和醫療專科列出醫生名單和檢驗申請數量。

第4章：美國潛伏性結核感染檢測市場：依檢測類型分類的估算與趨勢分析

  • 美國潛伏性結核感染檢測市場：波動分析（依檢測類型分類）
  • 美國潛伏性結核感染檢測市場展望：依檢測類型分類
  • 市場規模、預測與趨勢分析（2021-2033）：涵蓋以下內容：
  • 干擾素-γ釋放試驗（IGRA）
    • QFT
    • T. SPOT
  • 結核菌素皮膚反應（TST）

第5章：美國潛伏性結核感染檢測市場：按應用領域分類的估算與趨勢分析。

  • 美國潛伏性結核感染檢測市場：波動分析（按應用領域分類）
  • 美國潛伏性結核感染檢測市場展望：按應用領域分類
  • 市場規模、預測與趨勢分析（2021-2033）：涵蓋以下內容：
  • 肺結核患者的家庭接觸者
  • 愛滋病毒感染者
  • 其他

第6章：美國潛伏性結核感染檢測市場：依最終用途分類的估算與趨勢分析

  • 美國潛伏性結核感染檢測市場：依最終用途分類的波動分析
  • 美國潛伏性結核感染檢測市場展望：依最終用途分類
  • 市場規模、預測與趨勢分析（2021-2033）：涵蓋以下內容：
  • 診斷和檢測機構
  • 醫院/診所
  • 學術和研究機構

第7章 競爭情勢

  • 參與企業的分類
  • 近期趨勢及影響分析：依主要市場參與企業
  • 企業市場占有率分析（2025 年）
  • 主要企業公司簡介
    • QIAGEN
    • Euroimmun US
    • bioMerieux
    • Oxford Immunotec
    • SD Biosensor, INC.
    • Quest Diagnostics
    • LabCorp
    • ARUP Laboratories
    • Mayo Clinic Laboratories
    • BioReference Laboratories
    • Par Pharmaceutical, Inc.
Product Code: GVR-4-68040-861-8

U.S. Latent Tuberculosis Infection Detection Market Summary

The U.S. latent tuberculosis infection detection market size was estimated at USD 427.61 million in 2025 and is projected to reach USD 651.11 million by 2033, growing at a CAGR of 5.17% from 2026 to 2033. This growth is driven by an increasing risk of developing active tuberculosis infection from latent tuberculosis infection (LTBI), growing funding programs to promote TB diagnosis, aided by technological advancements in diagnostic methods.

According to estimates from the Centers for Disease Control and Prevention (CDC), up to 13 million people in the U.S. are believed to have LTBI, and without preventive treatment, about 5 %-10 % of those infected will develop active TB at some point in their lives.

Moreover, the growing focus on tuberculosis (TB) elimination and preventive care is creating a strong growth opportunity for the LTBI detection market. Public health authorities increasingly recognize that most active TB cases in the U.S. result from reactivation of latent infection rather than recent transmission. As a result, national TB elimination strategies have shifted toward identifying and treating LTBI before it progresses to active disease, placing greater emphasis on early and accurate diagnostic testing.

The risk of incident TB is influenced by various factors, such as age, underlying health conditions, and exposure settings, with older individuals and those in certain environments facing higher risks. Hence, managing LTBI through testing and treatment is crucial in reducing the risk of developing active TB and preventing the spread of the disease. Factors contributing to increased susceptibility to active TB from LTBI include:

U.S. Latent Tuberculosis Infection Detection Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. latent tuberculosis infection detection market report based on test, application, and end use:

  • Test Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
    • Interferon Gamma Released Assay (IGRA)
    • QFT
    • T.SPOT
    • Tuberculin Skin Test (TST)
  • Application Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
    • Household Contacts With Pulmonary TB
    • PLHIV
    • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
    • Diagnostic Laboratories
    • Hospitals/Clinics
    • Academic & Research Institutions

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Objectives
    • 1.3.1. Objective-1
    • 1.3.2. Objective-2
    • 1.3.3. Objective-3
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased database
    • 1.5.2. GVR's internal database
    • 1.5.3. Secondary sources
    • 1.5.4. Primary research
  • 1.6. Information or Data Analysis
    • 1.6.1. Data analysis models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis
      • 1.8.1.1. Approach 1: Commodity flow approach
      • 1.8.1.2. Approach 2: Country-wise market estimation using bottom-up approach
  • 1.9. List of Secondary Sources
  • 1.10. List of Primary Sources
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Test Snapshot
  • 2.3. Application and End-use Snapshot
  • 2.4. Competitive Insights

Chapter 3. U.S. Latent Tuberculosis Infection Detection Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook (Latent Tuberculosis Infection Detection Market)
    • 3.1.2. Related/ancillary market outlook (Tuberculosis Diagnostics Market)
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in risk of developing active Tuberculosis Infection from LTBI
      • 3.2.1.2. Increasing Funding Programs to Promote TB Diagnostics
      • 3.2.1.3. Technological Advancements in Diagnostics Methods
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited Awareness and Underdiagnosis of Latent TB
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Growing Focus on TB Elimination and Preventive Care
      • 3.2.3.2. Expansion of Community-Based and Targeted Screening Programs
    • 3.2.4. Market Challenge Analysis
      • 3.2.4.1. Low Disease Visibility and Competing Public Health Priorities
  • 3.3. U.S. Latent Tuberculosis Infection Detection Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
  • 3.4. Regulatory Framework
  • 3.5. Reimbursement Scenario
  • 3.6. Payment/ Reimbursement for Immigration Testing
  • 3.7. CLIA Labs in the U.S.
    • 3.7.1. List of all the CLIA Labs in the U.S
    • 3.7.2. List of CLIA and NYS Certified Labs that Perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their Volumes
    • 3.7.3. List of Physicians and Volumes Ordered of the Tests Split out by NPI, Geography, and Practice

Chapter 4. U.S. Latent Tuberculosis Infection Detection Market: Test Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Latent Tuberculosis Infection Detection Market: Test Movement Analysis
  • 4.3. U.S. Latent Tuberculosis Infection Detection Market by Test Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 4.5. Interferon Gamma Released Assay (IGRA)
    • 4.5.1. Interferon Gamma Released Assay (IGRA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Interferon Gamma Released Assay (IGRA) Market Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
    • 4.5.3. QFT
      • 4.5.3.1. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.3.2. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
    • 4.5.4. T. SPOT
      • 4.5.4.1. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.4.2. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 4.6. Tuberculin Skin Test (TST)
    • 4.6.1. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 5. U.S. Latent Tuberculosis Infection Detection Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Latent Tuberculosis Infection Detection Market: Application Movement Analysis
  • 5.3. U.S. Latent Tuberculosis Infection Detection Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 5.5. Household Contacts With Pulmonary TB
    • 5.5.1. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 5.6. PLHIV
    • 5.6.1. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.2. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.7.2. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 6. U.S. Latent Tuberculosis Infection Detection Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Latent Tuberculosis Infection Detection Market: End Use Movement Analysis
  • 6.3. U.S. Latent Tuberculosis Infection Detection Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 6.5. Diagnostic Laboratories
    • 6.5.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 6.6. Hospitals/Clinics
    • 6.6.1. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 6.7. Academic & Research Institutions
    • 6.7.1. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2025
  • 7.4. Key Company Profiles
    • 7.4.1. QIAGEN
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Euroimmun US
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. bioMerieux
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Oxford Immunotec
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. SD Biosensor, INC.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Quest Diagnostics
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. LabCorp
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. ARUP Laboratories
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Mayo Clinic Laboratories
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. BioReference Laboratories
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Par Pharmaceutical, Inc.
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 List of all the CLIA labs in the U.S
  • Table 4 List of CLIA and NYS certified labs that perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their volumes
  • Table 5 List of physicians and volumes ordered of the tests, split out by NPI, geography, and practice
  • Table 6 U.S. latent tuberculosis infection detection market, by test, 2021 - 2033 (USD Million)
  • Table 7 U.S. latent tuberculosis infection detection market, by application, 2021 - 2033 (USD Million)
  • Table 8 U.S. latent tuberculosis infection detection market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. latent tuberculosis infection detection market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. latent tuberculosis infection detection market snapshot
  • Fig. 10 Test snapshot
  • Fig. 11 Application and end-use snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market outlook
  • Fig. 14 Related/ancillary market outlook
  • Fig. 15 Market dynamics
  • Fig. 16 Market driver analysis (current & future impact)
  • Fig. 17 Market restraint analysis (current & future impact)
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 20 U.S. latent tuberculosis infection detection market, test outlook key takeaways
  • Fig. 21 U.S. latent tuberculosis infection detection market, test movement analysis
  • Fig. 22 IGRA market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 IGRA market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 24 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 26 QFT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 QFT market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 28 T.SPOT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 T.SPOT market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 30 U.S. latent tuberculosis infection detection market, application outlook key takeaways
  • Fig. 31 U.S. latent tuberculosis infection detection market, application movement analysis
  • Fig. 32 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 34 PLHIV market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 PLHIV market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 36 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 38 U.S. latent tuberculosis infection detection market, end use outlook key takeaways
  • Fig. 39 U.S. latent tuberculosis infection detection market, end use movement analysis
  • Fig. 40 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 42 Hospitals/Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Hospitals/Clinics market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 44 Academic & Research Institutions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Academic & Research Institutions market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
  • Fig. 46 Key company categorization
  • Fig. 47 Strategy mapping